1. Home
  2. BTCT vs PHIO Comparison

BTCT vs PHIO Comparison

Compare BTCT & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

HOLD

Current Price

$0.61

Market Cap

11.4M

Sector

Real Estate

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.05

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTCT
PHIO
Founded
2006
2003
Country
Singapore
United States
Employees
26
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4M
11.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
BTCT
PHIO
Price
$0.61
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
1.7M
410.8K
Earning Date
05-29-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$283.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.81
52 Week High
$3.12
$4.19

Technical Indicators

Market Signals
Indicator
BTCT
PHIO
Relative Strength Index (RSI) 29.01 50.70
Support Level $0.61 $1.00
Resistance Level $1.21 $1.14
Average True Range (ATR) 0.07 0.08
MACD -0.02 0.01
Stochastic Oscillator 6.86 70.00

Price Performance

Historical Comparison
BTCT
PHIO

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: